New Therapeutic Targets

New Development Compounds

Based on RNA biogenesis, and with the support of premier global discovery service provider Evotec, Abivax is building a small molecule chemical library with currently more than 2,200 compounds.

Inflammatory Diseases Further indications

Infectious Diseases Respiratory Syncytial Virus

Infectious Diseases Influenza and Dengue

Inflammatory Diseases

Abivax is currently exploring the opportunity to select new compounds beyond ABX464 for development in inflammatory diseases, in order to strengthen its strategic and scientific position in this therapeutic field.

Respiratory Syncytial Virus

Abivax is also targeting the infectious disease space, including first and foremost Respiratory Syncytial Virus (RSV), i.e. the cause of severe lower respiratory tract infections with substantial morbidity and mortality.

Abivax has already made substantial progress in RSV by identifying potential lead compounds, which are currently in the process of optimization.

Influenza and Dengue

Abivax is also continuing its research efforts to develop new product candidates to treat influenza as well as dengue.